Sickle Cell

Data show the average maximum cortical capillary RBC velocity is significantly greater in sickle cell mice compared to controls.

This study evaluates the likelihood that young adults with sickle cell disease or sickle cell trait will have a child or expand their family.

The approval of daratumumab and hyaluronidase-fihj plus carfilzomib and dexamethasone is for treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

There is currently not much known about the relationship between pregnancy outcomes and sickle cell trait.

There was no differences in complications by site in either the left or right subclavian vein.

The agent is the first therapeutic treatment indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses.

Hydroxyurea has been on the market for decades and yet it's underutilized as a treatment for sickle cell disease.

Ropeginterferon Alfa-2b-NJFT (Besremi) is approved by the FDA for the treatment of polycythemia vera regardless of a patient's treatment history.

A cross-sectional analysis suggests children aged 5-7 years old may begin to reckon with the burdens of sickle cell disease, while toddlers and infants may not.

New study finds that telehealth is a viable option for treating sickle cell anemia patients in rural populations.

Expert hematologists comment on the use of crizanlizumab in reducing painful crisis frequency in sickle cell disease and share their experience with the drug in clinical practice.

John J. Strouse, MD, PhD, and Sophie M. Lanzkron, MD, MHS, discuss the real-world significance of voxelotor for the treatment of sickle cell disease.

Voxelotor has the potential to decrease long-term problems in pediatric sickle cell disease.

Kim Smith-Whitley, MD, discussed her research on voxelotor as treatment for children with sickle cell disease.

Voxelotor study results show it’s just as effective in children as adults and adolescents.

Jeffrey D. Lebensburger, DO, MSPH, reviews data and key findings from the 72-week analysis of the HOPE study using voxelotor for patients with sickle cell disease.

Experts in hematology discuss NHLBI guideline recommendations for the screening and monitoring of anemia-related disease manifestations as well as goals of therapy for patients with sickle cell disease.

Obstructive sleep apneas and overnight hypoxemia are more likely to develop in patients with sickle cell disease.

Sophie M. Lanzkron, MD, MHS, and Jeffrey D. Lebensburger, DO, MSPH, comment on renal complications and outcomes that can result from sickle cell disease.

Dr John J. Strouse leads the discussion on pulmonary complications that can arise because of sickle cell disease.

The Firmicutes/Bacteroidetes ratio was lower for patients with sickle cell disease compared to a healthy control group.

Ketamine was not superior to morphine in reducing pain scores.

Sophie M. Lanzkron, MD, MHS, and Jeffrey D. Lebensburger, DO, MSPH, review the underlying pathophysiology of acute multisystem organ failure and resulting cerebrovascular and neurologic complications associated with sickle cell disease.

Jeffrey D. Lebensburger, DO, MSPH, and John J. Strouse, MD, PhD, comment on the serious complications of anemia and hemolysis caused by sickle cell disease and the impact on pediatric patients vs adults.

Expert hematologists review the presentation and diagnosis of sickle cell disease and the resulting effect of anemia and hemolysis on a patient’s quality of life.